Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Watz, D. Bock, M. Meyer, K. Schierhorn, K. Vollhardt, C. Woischwill, F. Pedersen, A. Kirsten, K. M. Beeh, W. Meyer-Sabellek, H. Magnussen, J. Beier (Grosshansdorf, Henningsdorf, Wiesbaden, Germany). Late-breaking abstract: Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study. Eur Respir J 2011; 38: Suppl. 55, 4492

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 LATE-BREAKING ABSTRACT: A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma Source: Annual Congress 2009 - Novel approaches in asthma Year: 2009 Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 STRIDE-2 trial: a placebo-controlled study for sitaxsentan in PAH Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Umeclidinium in patients with COPD: a randomised, placebo-controlled study Source: Eur Respir J 2014; 43: 72-81 Year: 2004 Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009 Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007 Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021 Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008 Glycopyrronium does not affect QT interval in healthy subjects: A randomized, 3-period cross-over, placebo- and positive-controlled study Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial Source: Annual Congress 2010 - COPD exacerbation Year: 2010 Inhaled racemic adrenalin versus saline in acute bronchiolitis, a multicenter randomized double-blind clinical trial Source: Annual Congress 2012 - New insights into respiratory infections in children Year: 2012 A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis Source: Eur Respir J 2015; 46: 1021-1032 Year: 2015 A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008 Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers: a randomised, placebo controlled, cross-over study Source: Eur Respir J 2003; 22: Suppl. 45, 49s Year: 2003